CNR1 and GPR55 as early biomarkers of type 1 diabetes
The use of CNR1 and GPR55 receptor expression levels in CD4+ lymphocytes provides a non-invasive, early diagnostic method for T1D, addressing the challenge of late detection by indicating insulitis onset before beta cell loss, enabling timely intervention.
Patent Information
- Application Number
- PCT/ES2024/070292
- Authority / Receiving Office
- WO · WO
- Patent Type
- Applications
- Current Assignee / Owner
- Priority Date
- 2023-05-17
- Filing Date
- 2024-05-16
- Publication Date
- 2024-11-21
AI Technical Summary
Current methods lack effective biomarkers for early diagnosis of type 1 diabetes (T1D) before the loss of functional beta cell mass, leading to late detection and inadequate intervention.
The use of expression levels of CNR1 and GPR55 receptors in peripheral blood mononuclear cells, particularly in circulating CD4+ lymphocytes, as non-invasive biomarkers to detect the onset of insulitis prior to beta cell loss, allowing for early diagnosis and intervention.
Enables early and minimally invasive detection of T1D onset, facilitating timely intervention and preventing diabetic ketoacidosis, applicable in both genetically predisposed and non-predisposed patients, with significant correlation between receptor overexpression and disease development.
Smart Images

Figure 000021 
Figure 000022 
Figure 00000020_0000
Abstract
Description
[0001] CNR1 AND GPR55 AS EARLY BIOMARKERS OF DIABETES
[0002] TYPE 1
[0003] DESCRIPTION
[0004] FIELD OF INVENTION
[0005] The present invention falls within the field of Medicine and more specifically, is framed within the study, diagnosis and evaluation of the development of type I diabetes.
[0006] STATE OF THE PRIOR ART
[0007] Insulin-dependent diabetes, i.e., type 1 diabetes mellitus (T1D), is an incurable autoimmune disease that leads to the progressive destruction of insulin-producing beta cells until the total loss of functional beta cell mass. This destruction results in dependence on exogenous insulin for survival. People with T1D are at daily risk of hyperglycemia and hypoglycemia, the latter of which is potentially fatal. Furthermore, uncontrolled blood glucose increases the risk of macrovascular and microvascular complications.
[0008] This condition is triggered by a combination of genetic and environmental factors. However, genetic predisposition accounts for less than 50% of cases.
[0009] T1D presents with insulitis, or inflammation of the islets of Langerhans. The islets of Langerhans are a group of endocrine tissues located in the pancreas that help regulate glucose levels. The infiltration of immune cells (B and T lymphocytes, macrophages, and dendritic cells) into the islets of Langerhans leads to atrophy and the disappearance of the insulin-producing beta cells. This process, called insulitis, plays a key role in the development of T1D, but is also a pathophysiological factor in type 2 diabetes.
[0010] As noted above, T1D, unlike type 2, is an autoimmune disease, so it characteristically presents autoantibodies (AA). Autoantibodies are antibodies developed by the immune system that act directly against one or more of the individual's own antigens. The AAs associated with T1D are varied and range from cytoplasmic autoantibodies of pancreatic islet cells to insulin autoantibodies, including glutamic acid decarboxylase autoantibodies, GAD65 autoantibodies, insulinoma-associated autoantibodies, IA-2A, ICA512 autoantibodies, protein tyrosine phosphatase-like autoantibodies, or zinc transporter 8 autoantibodies (ZnT8A).
[0011] The natural evolution of T1D is progressive and goes through three stages.
[0012] Stage 1: Autoantibodies (AA) appear; at this stage, there is no insulitis or disease yet. It can be detected by blood tests, but only when multiple AAs are present, which occurs in only 70% of cases.
[0013] Stage 2: onset of insulitis but without the appearance of hyperglycemia or hypoinsulinemia.
[0014] Stage 3: Onset of the disease. T1D is diagnosed based on blood glucose, hypoinsulinemia, and autoantibodies. By this stage, the remaining beta cell count is already very low.
[0015] In the early stages of the disease, a remnant of insulin-producing beta cells persists for several years. Scientific efforts are focused on preserving these beta cells in patients. To achieve this, in addition to developing effective treatment, early diagnosis is crucial. Early diagnosis is defined as the onset of insulitis, before the loss of the critical functional mass of beta cells. Therefore, this diagnosis should occur before the clinical onset of the disease (stage 3), when there is already sufficient beta cell loss to lead to problems with blood glucose control and insulin metabolism, i.e., hypoinsulinemia and subsequent hyperglycemia. The possibility of early detection in the early stages of disease development would guide the design of a new therapeutic approach to prevent or delay the onset of T1D.Prophylactic treatments that delay the onset already exist, such as the recently FDA-approved teplizumab.
[0016] Currently, there are no biomarkers for early diagnosis that determine the onset of insulitis prior to onset. It should be noted that neither the presence of autoantibodies nor genetic predisposition leads to the onset of T1D in all cases. Diagnosis is currently based on the detection of hyperglycemia, a lack of C peptide, and the presence of autoantibodies. Therefore, patients are only detected when sufficient beta-cell mass has been lost for T1D to develop and blood glucose levels are insufficiently maintained within a normal range, i.e., when insulin deficiency develops.
[0017] The endocannabinoid system plays an important role in metabolic and immune modulation in rodents and humans. The endocannabinoid system is composed of at least two G protein-coupled transmembrane receptors, cannabinoid receptor 1 (CB1R) and cannabinoid receptor 2 (CB2R), their ligands, and the synthesizing and degradative enzymes. CB2R, encoded by the CNR2 gene, is expressed primarily in immune cells, and to a lesser extent in the brain, and its activation reduces cytokine release and immune cell proliferation; CB2R is considered a key regulator of the immune response. CB1R, encoded by the CNR1 gene, is expressed in various tissues, including neurons in the brain, hepatocytes, muscle cells, and beta cells in the pancreas. More recently, it has been observed that CB1R is also expressed in immune cells and plays an important role in inflammation.GPR55, encoded by the GPR55 gene, is a G protein-coupled receptor that can be activated by both lysophosphatidylinositol and certain cannabinoids. Its involvement in the endocannabinoid system is being studied and debated, and it appears to play a relevant role in the regulation of bone metabolism, the control of inflammatory pain, and tumor cell proliferation.
[0018] Several pathologies present with a dysregulation of the endocannabinoid tone, including type 2 diabetes. Specifically, the expression of CB1R is upregulated in multiple tissues, including the islets of Langerhans, in individuals with obesity and type 2 diabetes (1) and some studies point to it as a possible therapeutic target (2). In this sense, antagonist drugs of CB1R receptors used in conjunction with potassium channel openers for the treatment of T1D and other related conditions have been described (3). On the other hand, it has been shown that GPR55 plays an important role in the regulation of the physiology of the islets of Langerhans (4).
[0019] Another recent human study performed a postmortem analysis of the pancreas of healthy individuals and patients with diagnosed, long-term T1D. Among the individuals initially categorized as healthy, a group of patients without diabetes but positive for autoantibodies was identified. These patients can be classified as pre-diabetic or with a high likelihood of having developed long-term T1D. In the pancreatic samples from these patients, CB1R signaling was the most upregulated (5).
[0020] However, the use of CB1R expression levels as a biomarker for the diagnosis of T1D, or for its early detection or pre-onset, has not been considered. Nor has it been established to date whether these expression levels were elevated in patients with T1D or in individuals in the early stages of disease development.
[0021] BRIEF DESCRIPTION OF THE INVENTION
[0022] The present invention provides new early and non-invasive biomarkers of T1D: the expression levels of the CNR1 and GPR55 receptors in peripheral blood mononuclear cells. These receptors are early markers of the insulinitis process prior to the loss of functional beta cell mass and insulin deficiency. Their detection and quantification is carried out in blood samples, specifically in peripheral blood mononuclear cells, and more specifically in circulating CD4+ lymphocytes, resulting in a minimally invasive early diagnosis method that is safe for the patient and easy to implement.
[0023] Quantitative determination of the expression levels of these biomarkers allows for early diagnosis of the onset of insulitis prior to the loss of functional beta-cell mass. The expression levels of these biomarkers can be combined with, or precede, autoantibody (AA) detection in patients with a genetic predisposition, enabling early intervention and patient monitoring to prevent diabetic ketoacidosis. It can also be used in patients without a genetic predisposition, in combination with AA detection. It is therefore a diagnostic method prior to the onset of the disease.
[0024] Experimental data show how circulating CD4+ lymphocytes from patients with recent onset (less than 2 ± 2 months) of T1D express elevated levels of the CNR1 and GPR55 receptors compared to healthy patients. There are significant limitations when it comes to obtaining data for study from patients prior to the onset of the disease. The main limitation is the lack of a method for identifying such patients, a problem to which the present invention addresses. Population studies conducted to date in this regard, especially in Northern Europe, have collected blood and plasma samples for long-term storage, in order to monitor the individuals under study and identify those who ultimately develop T1D. However, there is no catalog of samples of cells isolated from peripheral blood on which to study markers such as those proposed in the present invention.
[0025] Conducting this type of study requires, in addition to obtaining and storing cell samples isolated from fresh blood for very long periods of time, a very large number of subjects to be studied due to the low prevalence of T1D in the population. Large population groups would be necessary to identify a sufficient number of patients who ultimately develop T1D to conduct a comparative study with statistically significant results.
[0026] Since there is no alternative method available to select this group of patients who are in a stage prior to the onset of T1D, there are no data available to compare the differential expression of biomarkers between this group of patients and healthy individuals.
[0027] It should be noted in this regard that the development of T1D is progressive, as mentioned above, and does not present as a flare or sudden onset. On the contrary, it is a progressive disease with no clear phenotype until the degradation of accumulated functional beta cell mass is sufficient to generate a physiologically evident failure. Thus, the expression levels of disease markers progressively increase with the development of the disease, which can take years to manifest physiologically. Therefore, it can be inferred that the expression levels of biomarkers presented by an individual once the onset of the disease occurs are very similar to those presented by that same individual before the onset of the disease.For this reason, patients with recent onset (less than 2 ± 2 months) of T1D have been selected for the identification of the markers of the invention.
[0028] Furthermore, thanks to the parallels with other pathologies and the studies conducted on them, it is concluded that overactivation in the pathological tissue is reflected in overactivation at the systemic level. Therefore, the overexpression of the markers detected at the systemic level, in this case CNR1 and GPR55, occurs simultaneously with that in the pancreas and reflects the degree of development of T1D.
[0029] Thus, the expression levels of CNR1 and / or GPR55 constitute systemic biomarkers that show an overactivation in the pathological tissue, in this case pancreatic, and that are overexpressed in CD4+ T lymphocytes isolated from blood samples of patients with recent onset (less than 2 ± 2 months) of T1D, as the closest possible approximation to the situation that patients show prior to the onset of the disease.
[0030] A first aspect of the invention describes the in vitro use of the expression levels of CNR1 and / or GPR55, preferably simultaneously, in CD4+ T lymphocytes as biomarkers to diagnose prior to the onset and / or predict T1D.
[0031] In the context of the present invention, GPR55 is defined as the nucleic acid molecules of sequence SEQ ID NO:1, which corresponds to the NCBI reference sequence: NG_050956.1
[0032] GPR55 is also defined as nucleic acid molecules that are transcribed into the mRNA sequence SEQ ID NO: 2, which corresponds to the NCBI reference sequence: NM_005683.4
[0033] In the context of the present invention, CNR1 is defined as the nucleic acid molecules SEQ ID NO: 3, which corresponds to the NCBI reference sequence: NC_000006.12.
[0034] CNR1 is also defined as the nucleic acid molecules that are transcribed into the following mRNA sequences:
[0035] SEQ ID NO: 4 which corresponds to the NCBI reference sequence: NM_016083.6,
[0036] SEQ ID NO: 5 which corresponds to the NCBI reference sequence: NM_001160226.3, SEQ ID NO: 6 which corresponds to the NCBI reference sequence: NM_001160258.3,
[0037] SEQ ID NO: 7 which corresponds to the NCBI reference sequence: NM_001160259.3,
[0038] SEQ ID NO: 8 corresponding to the NCBI reference sequence: NM_033181.4 (isoform b).
[0039] According to the results described below in the embodiments of the invention, overexpression of CNR1 and / or GPR55 in CD4+ T lymphocytes correlates with the subsequent onset of type 1 diabetes mellitus.
[0040] A second aspect of the invention describes a biomarker expression profile suitable for diagnosing prior to the onset and / or predicting type 1 diabetes mellitus, comprising the expression levels of CNR1 and / or GPR55, preferably simultaneously, in CD4+ T lymphocytes, where the overexpression of CNR1 and / or GPR55 is an indicator of early stages of type 1 diabetes mellitus.
[0041] A third aspect of the invention describes an in vitro method for obtaining data useful for diagnosing prior to the onset and / or predicting type 1 diabetes mellitus, which comprises measuring the expression levels of CNR1 and / or GPR55, preferably simultaneously, in CD4+ T lymphocytes previously isolated from a blood sample previously isolated from an individual.
[0042] A fourth aspect of the invention describes an in vitro method for diagnosing prior to the onset and / or predicting severe type 1 diabetes mellitus, comprising: a) measuring the expression levels of one or more of CNR1 and / or GPR55, preferably simultaneously, in CD4+ T lymphocytes previously isolated from a blood sample previously isolated from an individual, b) comparing the values obtained with those of a reference sample obtained from healthy control individuals, and c) classifying the individual in the group of individuals who will suffer from type 1 diabetes when the levels of CNR1 and / or GPR55 are differentially expressed upwards with respect to the samples from healthy control individuals.
[0043] The methods of the invention can be applied to samples from individuals of either sex, i.e., men or women, and of any age. They are preferably carried out on isolated samples from individuals who have autoantibodies associated with T1D, such as pancreatic islet cell cytoplasmic autoantibodies, insulin autoantibodies, glutamic acid decarboxylase autoantibodies, GAD65 autoantibodies, insulinoma-associated autoantibodies, IA-2A, ICA512 autoantibodies, protein tyrosine phosphatase-like autoantibodies, or zinc transporter-8 (ZnT8A) autoantibodies.
[0044] In the present invention, "prognosis" refers to the expected course of a disease and refers to the assessment of the probability that a subject suffers from a disease, as well as the assessment of its onset, stage of development, evolution, or regression, and / or the prognosis for the future course of the disease. As will be understood by those skilled in the art, such an assessment, although preferred, may not typically be accurate for 100% of the subjects to be diagnosed. The term, however, requires that a statistically significant portion of the subjects can be identified as suffering from the disease or being predisposed to it.Whether a part is statistically significant can be readily determined by the person skilled in the art using various well-known statistical evaluation tools, for example, determination of confidence intervals, determination of significance P values, Student's test or Fisher's discriminant functions, nonparametric Mann-Whitney measures, Spearman's correlation, logistic regression, linear regression, area under the ROC curve (AUC). Preferably, the confidence intervals are at least 90%, at least 95%, at least 97%, at least 98%, or at least 99%. Preferably, the p value is less than 0.1, 0.05, 0.01, 0.005, or 0.0001.Preferably, the present invention allows the disease to be correctly detected differentially in at least 60%, more preferably in at least 70%, much more preferably in at least 80%, or even much more preferably in at least 90% of the subjects of a given group or population analyzed.
[0045] The first method of the invention involves comparing the expression levels of CNR1 and / or GPR55 with the CNR1 and / or GPR55 levels of a reference sample or with a median value from healthy individuals. In the context of the present invention, "reference sample" is understood to mean the sample used to determine the variation in the expression levels of CNR1 and / or GPR55 of the present invention. Preferably, reference samples are taken from several individuals and combined, such that the reference value reflects the average value of said molecules in the population of healthy individuals. "Reference value" is the expression level of CNR1 and / or GPR55 in a reference sample. The expression profile in the reference sample can preferably be generated from a population of two or more people. The population, for example, can contain 10, 15, 20, 30, 40, 50 or more people.
[0046] The detection of the amount of CNR1 and / or GPR55 expression product can be carried out by any means known in the state of the art.
[0047] Expression levels give rise to a specific "expression profile." The term "expression level," also known as "product quantity" or "expression product quantity," refers to biochemical material, specifically mRNA.
[0048] The measurement of the quantity or concentration of the expression product, preferably in a semi-quantitative or quantitative manner, can be carried out directly or indirectly. Direct measurement refers to the measurement of the quantity or concentration of the expression product, which is directly correlated with the number of RNA molecules. Such a signal (which we can also refer to as an intensity signal) can be obtained, for example, by measuring an intensity value of a chemical or physical property of said products. Indirect measurement includes measurements obtained from a secondary component or a biological measurement system (e.g., the measurement of cellular responses, ligands, "tags," or enzymatic reaction products).
[0049] The term "quantity," as used in the description, refers to, but is not limited to, the absolute or relative quantity of the expression products, as well as any other values or parameters related to them or that can be derived from them. Such values or parameters include signal intensity values obtained from any of the physical or chemical properties of said expression products obtained by direct measurement. Additionally, such values or parameters include all those obtained by indirect measurement, for example, any of the measurement systems described elsewhere in this document.The term "comparison," as used in the description, refers to, but is not limited to, the comparison of the quantity of CNR1 and / or GPR55 expression products in the biological sample to be analyzed, also known as the biological test sample, with a quantity of CNR1 and / or GPR55 expression products in one or more reference samples. The reference sample can be analyzed, for example, simultaneously or consecutively, along with the biological test sample.
[0050] In the invention, the method for determining the result, that is, the expression level of CNR1 and / or GPR55, need not be particularly limited.
[0051] The methods of the invention preferably carry out the determination of expression levels by:
[0052] (i) a micromath, and / or
[0053] (i) a method comprising PCR (polymerase chain reaction), such as real-time PCR or RT-PCR or digital PCR (dPCR) and / or
[0054] (iii) a Northern Blot and / or
[0055] (iv) an immunoassay, such as an immunohistochemical method or an ELISA-based method.
[0056] Real-time quantitative PCR (polymerase chain reaction) (usually abbreviated as RQ-PCR, RT-qPCR, rt-PCR, or qPCR) is a sensitive and reproducible mRNA expression quantification technique that can be used particularly for profiling mRNA expression in cells and tissues. Any method can be used to evaluate RT-PCR results, with the ACt and AACt methods being preferred. The AACt method is described in detail by Livak et al. (Ct = Cycle Threshold Values). The AACt method will include a 'control sample' and a 'subject sample'. The 'subject sample' is a sample from the subject to be tested. Typically, several replicates for each diluted concentration are used to derive the amplification efficiency. PCR amplification efficiency can be defined as percentage amplification (from 0 to 1).During the qPCR reaction, software typically measures for each sample the cycle number at which the fluorescence (indicator of PCR amplification) crosses an arbitrary line, the threshold. This crossing point is the Ct value. A microarray is an array on a solid substrate (usually a glass slide or a silicon thin-film cell) that analyzes large amounts of biological material, in this case a large amount of mRNA or, preferably, its reverse DNA transcripts, which are detectable by specific probes immobilized on the solid substrate.
[0057] A Northern blot involves the use of electrophoresis to separate RNA samples by size and subsequent detection with a hybridization probe complementary to (part of) the RNA target sequence of interest.
[0058] The term "immunoassay", as used in the present description, refers to any analytical technique based on the conjugation reaction of an antibody with an antigen. Examples of immunoassays known in the state of the art are, for example, but not limited to: immunoblot, enzyme-linked immunosorbent assay (ELISA), linear immunoassay (LIA), radioimmunoassay (RIA), immunofluoresence, x-map or protein chips. In another preferred embodiment, the immunoassay is an enzyme-linked immunosorbent assay or ELISA (Enzyme-Linked ImmunoSorbent Assay). ELISA is based on the premise that an immunoreactant (antigen or antibody) can be immobilized on a solid support, then placing said system in contact with a fluid phase containing the complementary reagent that can bind to a marker compound. There are different types of ELISA: direct ELISA, indirect ELISA or sandwich ELISA.The term "marker compound", as used in the present description, refers to a compound capable of giving rise to a chromogenic, fluorogenic, radioactive and / or chemiluminescent signal that allows the detection and quantification of the amount of antibodies against CNR1 and / or GPR55. The marker compound is selected from the list comprising radioisotopes, enzymes, fluorophores or any molecule capable of being conjugated with another molecule or detected and / or quantified directly. This marker compound can be bound to the antibody directly, or through another compound. Some examples of marker compounds that bind directly are, but are not limited to, enzymes such as alkaline phosphatase or peroxidase, radioactive isotopes such as 32P or 35S, fluorochromes such as fluorescein or metallic particles, for their direct detection by colohmmetry, autoradiography, fluorimetry, or metallography respectively.In the method of the present invention, mRNA expression can be normalized, preferably relative to the expression of another RNA molecule. Normalization methods are well known in the art.
[0059] Once the expression levels relative to the reference values have been determined, it is necessary to identify whether there are alterations in expression (increase or decrease in expression). Expression (and levels of the gene expression product) is considered increased in a sample of the subject matter when the levels of increase with respect to the reference sample are at least 5%, at least 10%, at least 15%, at least 20%, at least 25%, at least 30%, at least 35%, at least 40%, at least 45%, at least 50%, at least 55%, at least 60%, at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, at least 100%, at least 110%, at least 120%, at least 130%, at least 140%, at least 150%, at least 160%, at least 170%, at least 180%, at least 190%, at least 200%, at least 210%, at least 220%, at least 230%, at least 240%, at least 250%, at least 260%, at least 270%, at least 280%, at least 290%, at least 300%, at least 310%, at least 320%, at least 330%, at least 340%, at least 350%, at least 360%, at least 370%, at least 380%, at least 390%, at least 400%, at least 410%, at least 420%, at least 430%, at least 440%, at least 450%, at least 460%, at least 470%, at least 480%, at least 490%, at least 500%, at least 510%, at least 520%, at least less than 140%, at least 150%, or more.Similarly, expression is considered decreased when its levels decrease relative to the reference sample by at least 5%, at least 10%, at least 15%, at least 20%, at least 25%, at least 30%, at least 35%, at least 40%, at least 45%, at least 50%, at least 55%, at least 60%), at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, at least 100% (i.e., absent).
[0060] The invention provides a method for assigning a human subject to one of two groups: group 1, comprising subjects identifiable by the method of the invention, and group 2, which represents the remaining subjects. Individuals identifiable by the method of the invention would be those with overexpressed levels of CNR1 and / or GPR55. This group of patients would be classified as those who will develop type 1 diabetes.
[0061] A fifth aspect of the invention describes a kit or device comprising at least one or more oligonucleotides capable of hybridizing with CNR1 and GPR55 mRNAs under stringent conditions.
[0062] In a preferred embodiment, the kit or device of the invention comprises: (a) means for detecting the expression levels of CNR1 and / or GPR55 in a biological sample obtained from the subject.
[0063] In a more preferred embodiment, the kit or device of the invention further comprises:
[0064] (b) means to compare the level of expression (a) with a reference sample.
[0065] In particular embodiments, the kit is selected from (a) a kit suitable for POR, (b) a kit suitable for Northern blotting, (c) a kit suitable for microarray analysis, and (d) an immunoassay. Two or more of these embodiments may also be combined, such that the kit may comprise, for example, both (a) and (c).
[0066] In a preferred embodiment the kit or device comprises at least one or more oligonucleotides capable of hybridizing with CNR1 and / or GPR55.
[0067] It is preferred that said oligonucleotide(s) be capable of doing so under stringent conditions. Stringency is a term used in hybridization experiments that reflects the degree of complementarity between the oligonucleotide and the nucleic acid; the greater the stringency, the greater the percentage of homology between the probe and the nucleic acid bound to the filter. Those skilled in the art are well aware that temperature and salt concentrations have a direct effect on the results obtained. It is recognized that hybridization results are related to the number of degrees below the Tm (melting temperature) of the DNA on which the experiment is performed. Stringent conditions are often defined as a wash with 0.1X SSC (saline-sodium citrate (SSC) buffer at 65°C. (SSC is usually provided as a 20X stock solution, consisting of 3 M sodium chloride and 300 mM trisodium citrate (adjusted to pH 7.0 with HCl)).
[0068] The kit or device of the invention may comprise controls, program instructions and information necessary to carry out any of the methods of the invention.
[0069] Another aspect of the invention relates to the use of the kit or device of the invention in the method of the invention in any of its embodiments, although its use is not particularly limited. Another aspect of the invention relates to a computer program comprising instructions for performing the procedure according to any of the methods of the invention.
[0070] In particular, the invention encompasses computer programs arranged on or within a carrier. The carrier may be any entity or device capable of supporting the program. Alternatively, the carrier could be an integrated circuit containing the program and adapted to execute, or be used to execute, the corresponding processes.
[0071] For example, programs could be embedded in a storage medium, such as a ROM, CD-ROM, or semiconductor ROM, a USB flash drive, or a magnetic recording medium, such as a floppy disk or hard disk. Alternatively, programs could be supported by a transmissible carrier signal; for example, this could be an electrical or optical signal that could be transported via electrical or optical cable, by radio, or by any other means.
[0072] The invention also extends to computer programs adapted to allow any processing medium to implement the methods of the invention. The computer programs also encompass cloud applications based on this method.
[0073] Other aspects of the invention relate to the readable storage medium and the transmissible signal comprising program instructions necessary for the execution of the method of the invention by a computer.
[0074] Throughout the description and claims, the word "comprise" and its variants are not intended to exclude other technical features, additives, components, or steps. For those skilled in the art, other objects, advantages, and features of the invention will be apparent in part from the description and in part from the practice of the invention. The following examples and drawings are provided for illustrative purposes only and are not intended to limit the present invention.
[0075] DESCRIPTION OF THE FIGURES
[0076] Figure 1. Expression levels of cannabinoid receptors (A) CNR1, (B) CNR2, and (C) GPR55 in peripheral blood mononuclear cells (PBMCs) from healthy donors and patients with recent onset of T1D (matched for age, sex, and BMI). Data show real-time PCR. Data were analyzed using a t-test.
[0077] Figure 2. Expression levels of cannabinoid receptors (A) CNR1, (B) CNR2, and (C) GPR55 in circulating CD4+ T cells from healthy donors and patients with recent onset of T1D (matched for age, sex, and BMI). Data show real-time PCR. Data were analyzed by t-test. *p < 0.05.
[0078] DETAILED DESCRIPTION OF THE INVENTION
[0079] Cannabinoid receptors as biomarkers of type 1 diabetes
[0080] Blood samples were taken from healthy patients and from patients presenting onset (at the first appointment after diagnosis, less than 2 ± 2 months) of T1D.
[0081] The inclusion criteria for T1D were: T1D with routine follow-up at the Diabetes Unit of the Regional University Hospital of Malaga, aged 18-65 years, inclusive. HbA1c <10%. Normal weight, defined as BMI 18.5 - 24.9, inclusive. The inclusion criteria for control patients were: no T1D or direct family history of T1D. Age and BMI equal to the T1D group. HbA1c <5.7%. Exclusion criteria were: inflammatory or autoimmune disease other than T1D, patients with type 2 diabetes mellitus, or insulin resistance.
[0082] Concentration of used cells
[0083] Peripheral blood mononuclear cells (PBMCs) were obtained from fresh blood samples by centrifugation in Ficoll. After PBMC isolation, CD4+ cells were isolated from PBMCs using antibodies attached to magnetic beads.
[0084] RNA was extracted from both PBMC samples (Figure 1) and CD4+ lymphocytes (Figure 2).
[0085] Gene expression of CNR1, CNR2, and GPR55 receptors in PBMC samples was analyzed by real-time PCR (RT-PCR) using Taqman FAM probes for each receptor in multiplexes with B-ACTIN- / C as the reference gene. B-ACTIN and TBP were tested as reference genes, and B-ACTIN was ultimately chosen as the more robust gene for all cell types. CD4+ T cells were isolated from peripheral blood mononuclear cells (PBMCs) of patients at the onset of T1D (n=18) and non-diabetics (n=10), and RNA was extracted. The expression of CNR1, CNR2, and GPR55 was also analyzed by real-time PCR.
[0086] The expression of cannabinoid receptors on CD4+ T cells (Figure 2) is altered in patients with onset of T1D. Specifically, the CB1R and GPR55 receptors are elevated in patients with recent onset of T1D compared to non-diabetics. On the other hand, the CB2R receptor, classically linked to immune response, is not modified.
[0087] CD4+ T cells derived from patients with recent onset of T1D expressed 1.5 times more C / V 1-full length than those from control patients (p < 0.05), and none expressed CNR1-b.
[0088] The maximum normalized expression of CNR1 in CD4+ T lymphocytes of control patients was 3.42, whereas patients with recent onset of T1D showed an expression ranging from 0.1 to 530.6. Regarding GPR55, the maximum expression in CD4+ T cells in control patients was 2.63, and in patients with recent onset of T1D the expression ranged from 0.2 to 11.7.
[0089] The difference in the level of expression in CD4+ T lymphocytes of both CNR1 and GPR55 between patients with recent onset of T1D and healthy individuals was statistically significant (p < 0.05), (Figure 2), with both genes being overexpressed in patients with recent onset of T1D.
[0090] There is an inverse relationship between the expression of CNR1 and GPR55 in healthy patients, with a decrease in GPR55 in those with higher CNR1 levels. Meanwhile, in patients with T1D onset, there is an increase in the expression levels of both genes.
[0091] References
[0092] 1. Buraczynska M, et al. Common polymorphism in the cannabinoid type 1 receptor gene (CNR1) is associated with microvascular complications in type 2 diabetes. J Diabetes Complications. 2014 Jan-Feb;28(1):35-9. doi:
[0093] 10.1016 / j.jdiacomp.2013.08.005. Epub 2013 Sep 24. PMID: 24075694. 2. Ghosh A, Peyot ML, Leung YH, Ravenelle F, Madiraju SRM, Prentki M. A peripherally restricted cannabinoid-1 receptor inverse agonist promotes insulin secretion and protects from cytokine toxicity in human pancreatic islets. Eur J Pharmacol. 2023 Apr 5;944:175589. doi: 10.1016 / j.ejphar.2023.175589. Epub 2023 Feb 9. PMID: 36773683.
[0094] 3. W02006045799. Pharmaceutical compositions comprising CB1 cannabinoid receptor antagonists and potassium channel openers for the treatment of diabetes mellitus type I, obesity and related conditions.
[0095] 4. Liu B, Song S, Ruz-Maldonado I, Pingitore A, Huang GC, Baker D, Jones PM, Persaud SJ. GPR55-dependent stimulation of insulin secretion from isolated mouse and human islets of Langerhans. Diabetes Obes Metab. 2016 Dec;18(12):1263-1273. doi: 10.1111 / dom.12780. Epub 2016 Sep 29. PMID: 27561953.
[0096] 5. Yip L, Fuhlbrigge R, Alkhataybeh R, Fathman CG. Gene Expression Analysis of the Pre-Diabetic Pancreas to Identify Pathogenic Mechanisms and Biomarkers of Type 1 Diabetes. Front Endocrinol (Lausanne) 2020; 11 :990.
Claims
CLAIMS 1. In vitro use of GPR55 and / or CNR1 expression levels in CD4+ T lymphocytes isolated from peripheral blood samples as biomarkers for pre-diagnosing and / or predicting type 1 diabetes mellitus.
2. The use according to the preceding claim, characterized in that it comprises the levels of expression GPR55 and CNR1 simultaneously.
3. An in vitro method for obtaining useful data for diagnosing prior to the onset and / or predicting type 1 diabetes mellitus, which comprises measuring the level of expression of GPR55 and / or CNR1 in CD4+ T lymphocytes isolated from peripheral blood samples previously isolated from an individual.
4. The in vitro method for obtaining useful data according to the preceding claim, characterized in that the expression levels of GPR55 and CNR1 are measured simultaneously.
5. An in vitro method for diagnosing prior to onset and / or predicting type 1 diabetes mellitus comprising: a) measuring the level of expression of one or more of GPR55 and / or CNR1 in CD4+ T lymphocytes isolated from a peripheral blood sample previously isolated from an individual, b) comparing the value obtained with that of a reference sample obtained from healthy control individuals, and c) classifying the individual in the group of individuals who will suffer from type 1 diabetes when the level of GPR55 and / or CNR1 is differentially expressed upwards with respect to the sample from healthy control individuals.
6. The in vitro method according to the preceding claim, characterized in that in step a) the expression levels of GPR55 and CNR1 are measured simultaneously.
7. The method according to any of claims 3 to 6, wherein the isolated sample comes from an individual who presents autoantibodies associated with type I diabetes, such as cytoplasmic autoantibodies of the cells of the pancreatic islets, autoantibodies against insulin, decarboxylase autoantibodies of the glutamic acid, GAD65 autoantibodies, insulinoma-associated autoantibodies, IA-2A, ICA512 autoantibodies, protein tyrosine phosphatase-like autoantibodies or zinc transporter-8 (ZnT8A) autoantibodies.
8. The method according to any of claims 3 to 8, characterized in that the expression levels can be obtained by: (i) a microarray, and / or (i) a method comprising PCR (polymerase chain reaction), such as real-time PCR or RT-PCR and / or (iii) a Northern Blot and / or (iv) an immunoassay, such as an immunohistochemistry method or an ELISA-based method.
9. A kit or device comprising at least one oligonucleotide capable of hybridizing to GPR55 and CNR1 mRNAs simultaneously or sequentially under stringent conditions.
10. Use of the kit or device according to the preceding claim for carrying out the method according to claims 3-8.
Citation Information
Patent Citations
In vitro assay for early diagnosis of diabetes mellitus type 1
US20100143919A1
Inflammatory markers for detection and prevention of diabetes mellitus
WO2002048715A2
Methods to diagnose type 1 diabetes by measuring cytokine and / or chemokine expression profiles.
WO2009015472A1
Materials and methods relating to a g-protein coupled receptor
WO2009138744A1
Method of predicting risk for type 1 diabetes
WO2014207312A2
